Inflammation and Pain Post Cataract Surgery - Pipeline Insight, 2021

DelveInsights, Inflammation and Pain Post Cataract Surgery Pipeline Insight, 2021, report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Inflammation and Pain Post Cataract Surgery pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Inflammation and Pain Post Cataract Surgery Understanding
Inflammation and Pain Post Cataract Surgery: Overview
A cataract is a dense cloudy area that forms in the lens of the eye. The problem is common in older people. It is the most common cause of vision loss in developed and developing countries. Cataract surgery is the most commonly performed surgical procedure. The minimally invasive cataract surgery technique with phacoemulsification is considered to be a minor procedure with less complications. However, post-operative problems such as ocular pain and inflammation can cause some problems. Despite surgical advances, post-cataract surgery inflammation is still a common cause of patient discomfort, delayed recovery and reduced visual outcome.

"Inflammation and Pain Post Cataract Surgery - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Inflammation and Pain Post Cataract Surgery pipeline landscape is provided which includes the disease overview and Inflammation and Pain Post Cataract Surgery treatment guidelines. The assessment part of the report embraces, in depth Inflammation and Pain Post Cataract Surgery commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Inflammation and Pain Post Cataract Surgery collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Inflammation and Pain Post Cataract Surgery R&D. The therapies under development are focused on novel approaches to treat/improve Inflammation and Pain Post Cataract Surgery.

Inflammation and Pain Post Cataract Surgery Emerging Drugs Chapters
This segment of the Inflammation and Pain Post Cataract Surgery report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Inflammation and Pain Post Cataract Surgery Emerging Drugs
APP13007: Formosa Pharmaceuticals
APP13007 derived from our proprietary APNT formulation platform, is an aqueous-based ophthalmic nanosuspension positioned for the treatment of post-operative pain and inflammatory eye conditions. The active ingredient in APP13007 is a potent corticosteroid agent whose efficacy and safety for dermatological use has been well established for more than 30 years in the US, Europe, and Japan. APP13007 will represent the first ophthalmic application of the known API. APP13007 completed Phase II studies in 2020 and has just started Phase III studies in the United States in March, 2021.
Further product details are provided in the report..

Inflammation and Pain Post Cataract Surgery: Therapeutic Assessment
This segment of the report provides insights about the different Inflammation and Pain Post Cataract Surgery drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Inflammation and Pain Post Cataract Surgery
There are approx. 3+ key companies which are developing the therapies for Inflammation and Pain Post Cataract Surgery. The companies which have their Inflammation and Pain Post Cataract Surgery drug candidates in the most advanced stage, i.e. Phase III include, Formosa Pharmaceuticals.
Phases
DelveInsights report covers around 3+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Inflammation and Pain Post Cataract Surgery pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Inflammation and Pain Post Cataract Surgery: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inflammation and Pain Post Cataract Surgery therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inflammation and Pain Post Cataract Surgery drugs.

Inflammation and Pain Post Cataract Surgery Report Insights
Inflammation and Pain Post Cataract Surgery Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Inflammation and Pain Post Cataract Surgery Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Inflammation and Pain Post Cataract Surgery drugs?
How many Inflammation and Pain Post Cataract Surgery drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inflammation and Pain Post Cataract Surgery?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Inflammation and Pain Post Cataract Surgery therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Inflammation and Pain Post Cataract Surgery and their status?
What are the key designations that have been granted to the emerging drugs?

Introduction
Executive Summary
Inflammation and Pain Post Cataract Surgery: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
APP13007: Formosa Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
OCS-01: Oculis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early stage products (Phase I/II)
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Inflammation and Pain Post Cataract Surgery Key Companies
Inflammation and Pain Post Cataract Surgery Key Products
Inflammation and Pain Post Cataract Surgery- Unmet Needs
Inflammation and Pain Post Cataract Surgery- Market Drivers and Barriers
Inflammation and Pain Post Cataract Surgery- Future Perspectives and Conclusion
Inflammation and Pain Post Cataract Surgery Analyst Views
Inflammation and Pain Post Cataract Surgery Key Companies
Appendix

List Of Tables

Table 1 Total Products for Inflammation and Pain Post Cataract Surgery
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Inflammation and Pain Post Cataract Surgery
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available